R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 12

Ben Bray; Sreeram V Ramagopalan

doi:10.57264/cer-2023-0092

R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 12

J Comp Eff Res. 2023 Jul;12(7):e230092. doi: 10.57264/cer-2023-0092. Epub 2023 Jun 22.

Authors

Ben Bray^{1

2}, Sreeram V Ramagopalan^{1

3}

Affiliations

¹ Lane Clark & Peacock, London, W1U 1DQ, UK.
² Department of Population Health Sciences, King's College London, London, SE1 3QD, UK.
³ Center for Pharmaceutical Medicine Research, King's College London, London, SE1 9NH, UK.

Abstract

In this latest update we highlight the final results from the RCT-DUPLICATE initiative, the publication of guidance from Haute Autorité de Santé (HAS), the joint viewpoint from the Institute for Quality and Efficiency in HealthCare (IQWIG) and the Belgian HealthCare Knowledge Center, and a position from the European Organization for Research and Treatment of Cancer (EORTC). Finally, we discuss how the NICE RWE framework has been implemented to allow consideration of RWE external control arms.

Keywords: Belgian Health Care Knowledge Center; European Organization for Research and Treatment of Cancer; Haute Autorité de Santé; Institute for Quality and Efficiency in Health Care; NICE; RCT-DUPLICATE; randomized controlled trials; real-world evidence.